MOA Life Plus Co. Ltd.
Financials
Valuation Metrics
MOA Life Plus Co. Ltd.'s Market Cap is ₩41B. At end of 2025 it was ₩773B. Ranked #2405 of 2,410 in KR market (top 100%), #1627 of 1,631 on KOSDAQ (top 100%), #231 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 4.09B KRW | KR#2,405/2,410 Sec#231/231 |
| Revenue | 10.46B KRW | KR#2,278/2,410 Sec#176/231 |
| Net Income | -13.71B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 32.47B KRW | KR#2,314/2,410 Sec#218/231 |
| Net Assets | 24.19B KRW | KR#2,234/2,410 Sec#208/231 |
| Employees | 59 | KR#1,968/2,410 Sec#174/231 |
| Value | ||
| P/B | 0.17x | KR#145/2,410 Sec#6/231 |
| P/S | 0.39x | KR#897/2,410 Sec#38/231 |
| FCF Yield | -148.42% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -56.69% | KR#2,287/2,410 Sec#202/231 |
| ROA | -42.22% | KR#2,341/2,410 Sec#213/231 |
| Op. Margin | -65.61% | KR#2,253/2,410 Sec#163/231 |
| Revenue Growth | -13.98% | KR#2,012/2,410 Sec#182/231 |
| Financial Health | ||
| Debt Ratio | 34.26% | KR#671/2,410 Sec#78/231 |
| Total Debt | 10.89B KRW | KR#1,590/2,410 Sec#143/231 |
| FCF | -6.08B KRW | KR#1,546/2,410 Sec#123/231 |
| Cash | 623.2M KRW | KR#2,351/2,410 Sec#223/231 |
| Current Ratio | 2.07x | KR#837/2,410 Sec#94/231 |
| Performance | ||
| 1Y Return | -94.65% | KR#2,371/2,410 Sec#231/231 |
| 1M Return | -61.38% | KR#2,368/2,410 Sec#231/231 |
| From 52W High | -95.12% | KR#2,407/2,410 Sec#231/231 |
| 1Y MDD | -95.00% | KR#2,404/2,410 Sec#231/231 |
| Trading | ||
| Volume | 1,835,525 shares | KR#97/2,410 Sec#5/231 |
| Trading Value | 376.9M KRW | KR#1,278/2,410 Sec#137/231 |
| Foreign Own. | 0.00% | KR—/2,410 Sec—/231 |
| Per Share | ||
| EPS | -629 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,110 KRW | KR#2,274/2,410 Sec#206/231 |
Company Info
Established in 1999 based on poly-gamma-glutamic acid source technology, the company is a bio new drug development firm listed on KOSDAQ in 2016. Utilizing HumaMAX and MucoMAX platforms, it focuses on new drug development and operates in health functional foods, functional cosmetics, pet care, and pharmaceutical distribution. The company holds a pipeline for rare disease treatments and manufactures and distributes health functional foods and functional cosmetics using immune-boosting functional ingredients.